{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:10:18Z","timestamp":1794575418369,"version":"4.9.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG078759"],"award-info":[{"award-number":["R01AG078759"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006085","name":"Office of Disease Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006085","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leslie Dan Faculty of Pharmacy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Denosumab is an injectable osteoporosis medication administered twice per year. Discontinuation of denosumab can result in rapid rebound fractures, but the evidence is limited on real-world persistence with denosumab. We conducted 2 parallel, population-based cohort studies leveraging (1) healthcare administrative data from Ontario, Canada (ON; 100% population) and (2) a 20% random sample of US Medicare beneficiaries (US). The first denosumab claim (US: 1\/2010-12\/2019; ON: 1\/2012-12\/2021) was identified using pharmacy claims (ON) and Medicare Parts D and B claims (US). Patients aged &amp;lt;66\u00a0yr, residing in long-term care (LTC), or with implausible data (eg, death before first claim) were excluded. We developed and applied an algorithm that used dosing and days between dispensations to clean denosumab claims. We assumed a days supply of 183\u00a0d for each dispensation and defined discontinuation as a 60-d gap in coverage. We estimated initial persistence, reinitiation, and switching to other osteoporosis medications using Kaplan\u2013Meier estimators, censoring on death, disenrollment (US only), LTC admission, or study end (12\/31\/2022 [ON], 12\/31\/2020 [US]). We also estimated the monthly proportion of patients with an on-time denosumab dose to explore time trends. We identified 168\u2009339 eligible individuals in ON (mean age\u2009=\u200978\u00a0yr; 90% female) and 97\u2009595 in the US (mean age\u2009=\u200977\u00a0yr; 90% female). In ON, the median time to denosumab discontinuation was longer (median 2.3\u00a0yr [ON] vs 1.7\u00a0yr [US]; 3-yr persistence: 44% [ON] vs 31% [US]), and time to reinitiation was shorter (median\u2009=\u20090.5\u00a0yr [ON] vs 1.9\u00a0yr [US]). In both populations, around 10% switched to another osteoporosis medication. Women and those with prior oral bisphosphonate use had longer durations of denosumab treatment in ON but not in the US. The proportion persisting with on-time doses did not increase over time in the US or ON. Research to improve persistence with denosumab and optimize post-denosumab treatment is critical.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf061","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T12:24:36Z","timestamp":1744374276000},"source":"Crossref","is-referenced-by-count":10,"title":["Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States"],"prefix":"10.1093","volume":"9","author":[{"given":"Kaleen N","family":"Hayes","sequence":"first","affiliation":[{"name":"Department of Health Services, Policy, and Practice, Center for Gerontology and Healthcare Research, Brown University School of Public Health , Providence, RI 02903 ,","place":["United States"]},{"name":"Department of Epidemiology, Brown University School of Public Health , Providence, RI 02903 ,","place":["United States"]},{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto , Toronto, ON M5S 3M2 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvam R","family":"Sendhil","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University School of Public Health , Providence, RI 02903 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulbh","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto , Toronto, ON M5S 3M2 ,","place":["Canada"]},{"name":"ICES , Toronto, ON M4N 3M5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R","family":"Zullo","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy, and Practice, Center for Gerontology and Healthcare Research, Brown University School of Public Health , Providence, RI 02903 ,","place":["United States"]},{"name":"Department of Epidemiology, Brown University School of Public Health , Providence, RI 02903 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D","family":"Berry","sequence":"additional","affiliation":[{"name":"Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife and Harvard Medical School , Boston, MA 02131 ,","place":["United States"]},{"name":"Department of Medicine, Beth Israel Deaconess Medical Center , Boston, MA 02215 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Oganisian","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health , Providence, RI 02903 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Adegboye","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy, and Practice, Center for Gerontology and Healthcare Research, Brown University School of Public Health , Providence, RI 02903 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M","family":"Cadarette","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto , Toronto, ON M5S 3M2 ,","place":["Canada"]},{"name":"ICES , Toronto, ON M4N 3M5 ,","place":["Canada"]},{"name":"Department of Public Health Sciences, Dalla Lana School of Public Health, University of Toronto , Toronto, ON M5T 3M7 ,","place":["Canada"]},{"name":"Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina , Chapel Hill, NC 27599 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2025052713274917500_ref1","volume-title":"StatPearls","author":"Hildebrand","year":"2024"},{"key":"2025052713274917500_ref2","volume-title":"Denosumab","author":"Osteoporosis Canada","year":"2019"},{"issue":"4","key":"2025052713274917500_ref3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/BOR.0b013e32833ac7fe","article-title":"Measuring and improving adherence to osteoporosis pharmacotherapy","volume":"22","author":"Cadarette","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"2025052713274917500_ref4","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00198-019-05051-1","article-title":"Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap","volume":"30","author":"Ban","year":"2019","journal-title":"Osteoporos Int"},{"issue":"S1","key":"2025052713274917500_ref5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/pds.5686","article-title":"Trends in osteoporosis drug initiation and use among community dwelling older adults","volume":"32","author":"Hayes","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2025052713274917500_ref6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2025052713274917500_ref7","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.bonr.2020.100267","article-title":"Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation","volume":"12","author":"Anastasilakis","year":"2020","journal-title":"Bone Rep"},{"issue":"6","key":"2025052713274917500_ref8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025052713274917500_ref9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025052713274917500_ref10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2025052713274917500_ref11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025052713274917500_ref12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jbmr.4049","article-title":"Osteoporosis management in the era of COVID-19","volume":"35","author":"Yu","year":"2020","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"10","key":"2025052713274917500_ref13","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s40618-022-01820-8","article-title":"COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine","volume":"45","author":"De Vincentis","year":"2022","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"2025052713274917500_ref14","doi-asserted-by":"publisher","first-page":"ziae027","DOI":"10.1093\/jbmrpl\/ziae027","article-title":"On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal","volume":"8","author":"Rzepka","year":"2024","journal-title":"JBMR Plus"},{"issue":"1p1","key":"2025052713274917500_ref15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1475-6773.2010.01194.x","article-title":"The residential history file: studying nursing home residents\u2019 long-term care histories","volume":"46","author":"Intrator","year":"2011","journal-title":"Health Serv Res"},{"key":"2025052713274917500_ref16","volume-title":"Drugs at FDA","author":"US Food & Drug Administration","year":"2024"},{"issue":"1","key":"2025052713274917500_ref17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00198-016-3693-5","article-title":"Understanding fragility fracture patients\u2019 decision-making process regarding bisphosphonate treatment","volume":"28","author":"Wozniak","year":"2017","journal-title":"Osteoporos Int"},{"key":"2025052713274917500_ref18","volume-title":"Increased risk of vertebral fracture after stopping denosumab","author":"Osteoporosis Canada","year":"2018"},{"key":"2025052713274917500_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07484-3","article-title":"Osteoporosis medication use over time in the United Statese and Canada","author":"Hayes","year":"2025","journal-title":"Osteoporos Int"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf061\/62914493\/ziaf061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/6\/ziaf061\/62914493\/ziaf061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/6\/ziaf061\/62914493\/ziaf061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:27:57Z","timestamp":1748366877000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf061\/8111443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf061","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,11]]},"article-number":"ziaf061"}}